Home » Gilead: Teva Files ANDA With FDA for Generic Viread
Gilead: Teva Files ANDA With FDA for Generic Viread
Gilead Sciences, Inc. Thursday announced receipt of a Paragraph IV Certification
Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) requesting
permission to manufacture and market a generic version of Viread (tenofovir disoproxil fumarate).
StreetInsider
StreetInsider
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May